{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:49:06Z","timestamp":1787068146354,"version":"build-2736575974"},"reference-count":101,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"DOI":"10.1093\/bmb\/ldh041","type":"journal-article","created":{"date-parts":[[2005,4,21]],"date-time":"2005-04-21T11:48:23Z","timestamp":1114084103000},"page":"65-81","source":"Crossref","is-referenced-by-count":45,"title":["Vaccines against bacterial meningitis"],"prefix":"10.1093","volume":"72","author":[{"given":"S.","family":"Segal","sequence":"first","affiliation":[{"name":"Department of Paediatrics, University of Oxford, Level 4, John Radcliffe Hospital, Oxford OX3 9DU, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Pollard","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University of Oxford, Level 4, John Radcliffe Hospital, Oxford OX3 9DU, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,3,31]]},"reference":[{"key":"key\n\t\t\t\t20180712075154_BIB1","doi-asserted-by":"crossref","unstructured":"Greenwood B (1999) The epidemiology of pneumococcal infection in children in the developing world. Philos Trans R Soc Lond B Biol Sci354, 777\u201385.","DOI":"10.1098\/rstb.1999.0430"},{"key":"key\n\t\t\t\t20180712075154_BIB2","doi-asserted-by":"crossref","unstructured":"Hargreaves RM , Slack MP, Howard AJ, Anderson E, Ramsay ME (1996) Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme. BMJ, 312, 160\u20131","DOI":"10.1136\/bmj.312.7024.160"},{"key":"key\n\t\t\t\t20180712075154_BIB3","unstructured":"Laurichesse H , Grimaud O, Waight P, Johnson AP, George RC, Miller E (1998) Pneumococcal bacteraemia and meningitis in England and Wales, 1993 to 1995. Commun Dis Public Health, 1, 22\u20137."},{"key":"key\n\t\t\t\t20180712075154_BIB4","doi-asserted-by":"crossref","unstructured":"O\u2019Dempsey TJ , McArdle TF, Lloyd-Evans N et al. (1994) Importance of enteric bacteria as a cause of pneumonia, meningitis and septicemia among children in a rural community in The Gambia, West Africa. Pediatr Infect Dis J, 13, 122\u20138.","DOI":"10.1097\/00006454-199402000-00009"},{"key":"key\n\t\t\t\t20180712075154_BIB5","doi-asserted-by":"crossref","unstructured":"Peltola H (2000) Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev, 13, 302\u201317.","DOI":"10.1128\/CMR.13.2.302-317.2000"},{"key":"key\n\t\t\t\t20180712075154_BIB6","doi-asserted-by":"crossref","unstructured":"Quagliarello VJ , Scheld WM (1993) New perspectives on bacterial meningitis. Clin Infect Dis, 17, 603\u201310.","DOI":"10.1093\/clinids\/17.4.603"},{"key":"key\n\t\t\t\t20180712075154_BIB7","doi-asserted-by":"crossref","unstructured":"von Reyn CF , Vuola JM (2002) New vaccines for the prevention of tuberculosis. Clin Infect Dis, 35, 465\u201374.","DOI":"10.1086\/341901"},{"key":"key\n\t\t\t\t20180712075154_BIB8","doi-asserted-by":"crossref","unstructured":"Smith AW , Bradley AK, Wall RA et al. (1988) Sequelae of epidemic meningococcal meningitis in Africa. Trans R Soc Trop Med. Hyg, 82, 312\u201320.","DOI":"10.1016\/0035-9203(88)90459-2"},{"key":"key\n\t\t\t\t20180712075154_BIB9","doi-asserted-by":"crossref","unstructured":"Davison KL , Ramsay ME (2003) The epidemiology of acute meningitis in children in England and Wales. Arch Dis Child, 88, 662\u20134.","DOI":"10.1136\/adc.88.8.662"},{"key":"key\n\t\t\t\t20180712075154_BIB10","doi-asserted-by":"crossref","unstructured":"Adams WG , Deaver KA, Cochi SL et al. (1993) Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA, 269, 221\u20136.","DOI":"10.1001\/jama.1993.03500020055031"},{"key":"key\n\t\t\t\t20180712075154_BIB11","doi-asserted-by":"crossref","unstructured":"Wenger JD , DiFabio J, Landaverde JM, Levine OS, Gaafar T (1999) Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four \u2018newly adopting\u2019 countries. Vaccine, 18, 736\u201342.","DOI":"10.1016\/S0264-410X(99)00269-8"},{"key":"key\n\t\t\t\t20180712075154_BIB12","doi-asserted-by":"crossref","unstructured":"Heath PT (1998) Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J, 17, S117\u201322.","DOI":"10.1097\/00006454-199809001-00005"},{"key":"key\n\t\t\t\t20180712075154_BIB13","doi-asserted-by":"crossref","unstructured":"Eskola J , Kayhty H, Takala AK et al. (1990) A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med, 323, 1381\u20137.","DOI":"10.1056\/NEJM199011153232004"},{"key":"key\n\t\t\t\t20180712075154_BIB14","doi-asserted-by":"crossref","unstructured":"Ward J , Brenneman G, Letson GW, Heyward WL (1990) Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H.influenzae Vaccine Study Group. N Engl J Med, 323, 1393\u20131401.","DOI":"10.1056\/NEJM199011153232006"},{"key":"key\n\t\t\t\t20180712075154_BIB15","doi-asserted-by":"crossref","unstructured":"Adegbola RA , Mulholland EK, Secka O, Jaffar S, Greenwood BM (1998) Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H.influenzae type b among Gambian children. J Infect Dis, 177, 1758\u201361.","DOI":"10.1086\/517440"},{"key":"key\n\t\t\t\t20180712075154_BIB16","doi-asserted-by":"crossref","unstructured":"Heath PT , Bowen-Morris J, Griffiths D, Griffiths H, Crook DW, Moxon ER (1997) Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T. Arch Dis Child, 77, 488\u201392.","DOI":"10.1136\/adc.77.6.488"},{"key":"key\n\t\t\t\t20180712075154_BIB17","doi-asserted-by":"crossref","unstructured":"McVernon J , Andrews N, Slack MP, Ramsay ME (2003) Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet, 361, 1521\u20133.","DOI":"10.1016\/S0140-6736(03)13171-6"},{"key":"key\n\t\t\t\t20180712075154_BIB18","unstructured":"McVernon J , Heath P (2003) Re-inforcement of Hib immunisation required. Commun Dis Public Health, 6, 2."},{"key":"key\n\t\t\t\t20180712075154_BIB19","doi-asserted-by":"crossref","unstructured":"Claesson BA , Schneerson R, Lagergard T et al. (1991) Persistence of serum antibodies elicited by Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants vaccinated at, 3, 5 and 12 months of age. Pediatr Infect Dis J, 10, 560\u20134.","DOI":"10.1097\/00006454-199108000-00002"},{"key":"key\n\t\t\t\t20180712075154_BIB20","doi-asserted-by":"crossref","unstructured":"Claesson BA , Trollfors B, Anderson PW et al. (1996) Serum antibodies in six-year-old children vaccinated in infancy with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J, 15, 170\u20132.","DOI":"10.1097\/00006454-199602000-00016"},{"key":"key\n\t\t\t\t20180712075154_BIB21","doi-asserted-by":"crossref","unstructured":"Rosenstein NE , Perkins BA, Stephens DS, Popovic T, Hughes JM (2001) Meningococcal disease. N Engl J Med, 344, 1378\u201388.","DOI":"10.1056\/NEJM200105033441807"},{"key":"key\n\t\t\t\t20180712075154_BIB22","doi-asserted-by":"crossref","unstructured":"Cartwright K , Noah N, Peltola H (2000) Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6\u20138October, 2000. Vaccine, 19, 4347\u201356.","DOI":"10.1016\/S0264-410X(01)00205-5"},{"key":"key\n\t\t\t\t20180712075154_BIB23","doi-asserted-by":"crossref","unstructured":"Greenwood B (1999) Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg, 93, 341\u201353.","DOI":"10.1016\/S0035-9203(99)90106-2"},{"key":"key\n\t\t\t\t20180712075154_BIB24","doi-asserted-by":"crossref","unstructured":"Maiden MC , Stuart JM (2002) Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet, 359, 1829\u201331.","DOI":"10.1016\/S0140-6736(02)08679-8"},{"key":"key\n\t\t\t\t20180712075154_BIB25","doi-asserted-by":"crossref","unstructured":"Morley SL , Pollard AJ (2001) Vaccine prevention of meningococcal disease, coming soon? Vaccine, 20, 666\u201387.","DOI":"10.1016\/S0264-410X(01)00410-8"},{"key":"key\n\t\t\t\t20180712075154_BIB26","doi-asserted-by":"crossref","unstructured":"Taha MK , Achtman M, Alonso JM et al. (2000) Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet, 356, 2159.","DOI":"10.1016\/S0140-6736(00)03502-9"},{"key":"key\n\t\t\t\t20180712075154_BIB27","unstructured":"Riou JY , Djibo S, Sangare L et al. (1996) A predictable comeback: the second pandemic of infections caused by Neisseria meningitidis serogroup A subgroup III in Africa, 1995. Bull WHO, 74, 181\u20137."},{"key":"key\n\t\t\t\t20180712075154_BIB28","doi-asserted-by":"crossref","unstructured":"Vogel G (2003) Infectious disease. Shortage of meningitis vaccine forces triage in Burkina Faso. Science, 299, 1499\u20131501.","DOI":"10.1126\/science.299.5612.1499a"},{"key":"key\n\t\t\t\t20180712075154_BIB29","doi-asserted-by":"crossref","unstructured":"Harrison LH , Pass MA, Mendelsohn AB et al. (2001) Invasive meningococcal disease in adolescents and young adults. JAMA, 286, 694\u20139.","DOI":"10.1001\/jama.286.6.694"},{"key":"key\n\t\t\t\t20180712075154_BIB30","unstructured":"Memish ZA , Alrajhi AA (2002) Meningococcal disease. Saudi Med J, 23, 259\u201364."},{"key":"key\n\t\t\t\t20180712075154_BIB31","doi-asserted-by":"crossref","unstructured":"Maiden MC , Spratt BG (1999) Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet, 354, 615\u201316.","DOI":"10.1016\/S0140-6736(99)00252-4"},{"key":"key\n\t\t\t\t20180712075154_BIB32","doi-asserted-by":"crossref","unstructured":"Trotter CL , Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet, 364, 365\u20137.","DOI":"10.1016\/S0140-6736(04)16725-1"},{"key":"key\n\t\t\t\t20180712075154_BIB33","doi-asserted-by":"crossref","unstructured":"Miller MA , Wenger J, Rosenstein N, Perkins B (1999) Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa. Pediatr Infect Dis J, 18, 1051\u20139.","DOI":"10.1097\/00006454-199912000-00005"},{"key":"key\n\t\t\t\t20180712075154_BIB34","doi-asserted-by":"crossref","unstructured":"Dull P , Rosenstein N (2001) Meningococcal disease and vaccines. Pediatr Ann, 30, 358\u201361.","DOI":"10.3928\/0090-4481-20010601-12"},{"key":"key\n\t\t\t\t20180712075154_BIB35","doi-asserted-by":"crossref","unstructured":"Perkins BA , Broome CV, Rosenstein NE, Schuchat A, Reingold AL (1997) Meningococcal vaccine in sub-Saharan Africa. Lancet, 350, 1708\u201310.","DOI":"10.1016\/S0140-6736(05)64314-0"},{"key":"key\n\t\t\t\t20180712075154_BIB36","doi-asserted-by":"crossref","unstructured":"Taha MK, Parent Du Chatelet I, Schlumberger M et al. (2002) Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol 2002;40, 1083\u20134","DOI":"10.1128\/JCM.40.3.1083-1084.2002"},{"key":"key\n\t\t\t\t20180712075154_BIB37","doi-asserted-by":"crossref","unstructured":"Finne J , Leinonen M, Makela PH (1983) Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet, 2, 355\u20137.","DOI":"10.1016\/S0140-6736(83)90340-9"},{"key":"key\n\t\t\t\t20180712075154_BIB38","doi-asserted-by":"crossref","unstructured":"Rosenstein NE , Fischer M, Tappero JW (2001) Meningococcal vaccines. Infect Dis Clin North Am, 15, 155\u201369.","DOI":"10.1016\/S0891-5520(05)70273-7"},{"key":"key\n\t\t\t\t20180712075154_BIB39","doi-asserted-by":"crossref","unstructured":"Oliver KJ , Reddin KM, Bracegirdle P et al. (2002) Neisseria lactamica protects against experimental meningococcal infection. Infect Immun, 70, 3621\u20136.","DOI":"10.1128\/IAI.70.7.3621-3626.2002"},{"key":"key\n\t\t\t\t20180712075154_BIB40","doi-asserted-by":"crossref","unstructured":"Sanchez S , Troncoso G, Criado MT, Ferreiros C (2002) In vitro induction of memory-driven responses against Neisseria meningitidis by priming with Neisseria lactamica. Vaccine, 20, 2957\u201363.","DOI":"10.1016\/S0264-410X(02)00224-4"},{"key":"key\n\t\t\t\t20180712075154_BIB41","doi-asserted-by":"crossref","unstructured":"Tondella ML , Popovic T, Rosenstein NE et al. (2000) Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol, 38, 3323\u20138.","DOI":"10.1128\/JCM.38.9.3323-3328.2000"},{"key":"key\n\t\t\t\t20180712075154_BIB42","doi-asserted-by":"crossref","unstructured":"Fusco PC , Michon F, Tai JY, Blake MS (1997) Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J Infect Dis,175, 364\u201372.","DOI":"10.1093\/infdis\/175.2.364"},{"key":"key\n\t\t\t\t20180712075154_BIB43","doi-asserted-by":"crossref","unstructured":"Bruge J , Bouveret-Le Cam N, Danve B, Rougon G, Schulz D (2004) Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine, 22, 1087\u201396.","DOI":"10.1016\/j.vaccine.2003.10.005"},{"key":"key\n\t\t\t\t20180712075154_BIB44","doi-asserted-by":"crossref","unstructured":"Nedelec J , Boucraut J, Garnier JM, Bernard D, Rougon G (1990) Evidence for autoimmune antibodies directed against embryonic neural cell adhesion molecules (N-CAM) in patients with group B meningitis. J Neuroimmunol, 29, 49\u201356.","DOI":"10.1016\/0165-5728(90)90146-E"},{"key":"key\n\t\t\t\t20180712075154_BIB45","doi-asserted-by":"crossref","unstructured":"Tappero JW , Lagos R, Ballesteros AM et al. (1999) Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA, 281, 1520\u20137.","DOI":"10.1001\/jama.281.16.1520"},{"key":"key\n\t\t\t\t20180712075154_BIB46","doi-asserted-by":"crossref","unstructured":"de Kleijn ED , de Groot R, Labadie J et al. (2000) Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2\u20133 and 7\u20138 years of age. Vaccine, 18, 1456\u201366.","DOI":"10.1016\/S0264-410X(99)00423-5"},{"key":"key\n\t\t\t\t20180712075154_BIB47","doi-asserted-by":"crossref","unstructured":"Boslego J , Garcia J, Cruz C et al. (1995) Efficacy, safety, and immunogenicity of a meningococcal group B (15, P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine, 13, 821\u20139.","DOI":"10.1016\/0264-410X(94)00037-N"},{"key":"key\n\t\t\t\t20180712075154_BIB48","doi-asserted-by":"crossref","unstructured":"Jodar L , Feavers IM, Salisbury D, Granoff DM (2002) Development of vaccines against meningococcal disease. Lancet, 359, 1499\u20131508.","DOI":"10.1016\/S0140-6736(02)08416-7"},{"key":"key\n\t\t\t\t20180712075154_BIB49","doi-asserted-by":"crossref","unstructured":"Urwin R , Russell JE, Thompson EA, Holmes EC, Feavers IM, Maiden MC (2004) Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun, 72, 5955\u201362.","DOI":"10.1128\/IAI.72.10.5955-5962.2004"},{"key":"key\n\t\t\t\t20180712075154_BIB50","doi-asserted-by":"crossref","unstructured":"Cadieux N , Plante M, Rioux CR, Hamel J, Brodeur BR, Martin D (1999) Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect Immun, 67, 4955\u20139.","DOI":"10.1128\/IAI.67.9.4955-4959.1999"},{"key":"key\n\t\t\t\t20180712075154_BIB51","doi-asserted-by":"crossref","unstructured":"Parkhill J , Achtman M, James KD et al. (2000) Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature, 404, 502\u20136.","DOI":"10.1038\/35006655"},{"key":"key\n\t\t\t\t20180712075154_BIB52","doi-asserted-by":"crossref","unstructured":"Tettelin H , Saunders NJ, Heidelberg J et al. (2000) Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science, 287, 1809\u201315.","DOI":"10.1126\/science.287.5459.1809"},{"key":"key\n\t\t\t\t20180712075154_BIB53","doi-asserted-by":"crossref","unstructured":"Jennings MP , Srikhanta YN, Moxon ER et al. (1999) The genetic basis of the phase variation repertoire of lipopolysaccharide immunotypes in Neisseria meningitidis. Microbiology, 145, 3013\u201321.","DOI":"10.1099\/00221287-145-11-3013"},{"key":"key\n\t\t\t\t20180712075154_BIB54","doi-asserted-by":"crossref","unstructured":"Pizza M , Scarlato V, Masignani V et al. (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science, 287, 1816\u201320.","DOI":"10.1126\/science.287.5459.1816"},{"key":"key\n\t\t\t\t20180712075154_BIB55","doi-asserted-by":"crossref","unstructured":"Poolman J , Berthet FX (2001) Alternative vaccine strategies to prevent serogroup B meningococcal diseases. Vaccine, 20 (Suppl 1), S24\u20136.","DOI":"10.1016\/S0264-410X(01)00283-3"},{"key":"key\n\t\t\t\t20180712075154_BIB56","doi-asserted-by":"crossref","unstructured":"Grandi G (2001) Antibacterial vaccine design using genomics and proteomics. Trends Biotechnol, 19, 181\u20138.","DOI":"10.1016\/S0167-7799(01)01600-6"},{"key":"key\n\t\t\t\t20180712075154_BIB57","doi-asserted-by":"crossref","unstructured":"Sun YH , Bakshi S, Chalmers R, Tang CM (2000) Functional genomics of Neisseria meningitidis pathogenesis. Nat Med, 6, 1269\u201373.","DOI":"10.1038\/81380"},{"key":"key\n\t\t\t\t20180712075154_BIB58","doi-asserted-by":"crossref","unstructured":"Dawson KG , Emerson JC, Burns JL (1999) Fifteen years of experience with bacterial meningitis. Pediatr Infect Dis J, 18, 816\u201322.","DOI":"10.1097\/00006454-199909000-00014"},{"key":"key\n\t\t\t\t20180712075154_BIB59","doi-asserted-by":"crossref","unstructured":"Djuretic T , Ryan MJ, Miller E, Fairley CK, Goldblatt D (1998) Hospital admissions in children due to pneumococcal pneumonia in England. J Infect, 37, 54\u20138.","DOI":"10.1016\/S0163-4453(98)90604-1"},{"key":"key\n\t\t\t\t20180712075154_BIB60","doi-asserted-by":"crossref","unstructured":"Shinefield HR , Black S (2000) Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr Infect Dis J, 19, 394\u20137.","DOI":"10.1097\/00006454-200004000-00036"},{"key":"key\n\t\t\t\t20180712075154_BIB61","doi-asserted-by":"crossref","unstructured":"Shinefield HR , Black S, Ray P et al. (1999) Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J, 18, 757\u201363.","DOI":"10.1097\/00006454-199909000-00004"},{"key":"key\n\t\t\t\t20180712075154_BIB62","doi-asserted-by":"crossref","unstructured":"Black S , Shinefield H, Fireman B et al. (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J, 19, 187\u201395.","DOI":"10.1097\/00006454-200003000-00003"},{"key":"key\n\t\t\t\t20180712075154_BIB63","doi-asserted-by":"crossref","unstructured":"Black SB , Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F (2001) Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J, 20, 1105\u20137.","DOI":"10.1097\/00006454-200112000-00002"},{"key":"key\n\t\t\t\t20180712075154_BIB64","doi-asserted-by":"crossref","unstructured":"Eskola J , Kilpi T, Palmu A et al. (2001) Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med, 344, 403\u20139.","DOI":"10.1056\/NEJM200102083440602"},{"key":"key\n\t\t\t\t20180712075154_BIB65","doi-asserted-by":"crossref","unstructured":"Pelton SI , Dagan R, Gaines BM et al. (2003) Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Vaccine, 21, 1562\u201371.","DOI":"10.1016\/S0264-410X(02)00681-3"},{"key":"key\n\t\t\t\t20180712075154_BIB66","doi-asserted-by":"crossref","unstructured":"Poolman JT (2004) Pneumococcal vaccine development. Expert Rev Vaccines, 3, 597\u2013604.","DOI":"10.1586\/14760584.3.5.597"},{"key":"key\n\t\t\t\t20180712075154_BIB67","doi-asserted-by":"crossref","unstructured":"Lipsitch M (1999) Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis, 5, 336\u201345.","DOI":"10.3201\/eid0503.990304"},{"key":"key\n\t\t\t\t20180712075154_BIB68","doi-asserted-by":"crossref","unstructured":"Lipsitch M (2001) Interpreting results from trials of pneumococcal conjugate vaccines: a statistical test for detecting vaccine-induced increases in carriage of nonvaccine serotypes. Am J Epidemiol, 154, 85\u201392.","DOI":"10.1093\/aje\/154.1.85"},{"key":"key\n\t\t\t\t20180712075154_BIB69","doi-asserted-by":"crossref","unstructured":"Obaro SK (2000) Confronting the pneumococcus: a target shift or bullet change? Vaccine, 19, 1211\u201317.","DOI":"10.1016\/S0264-410X(00)00262-0"},{"key":"key\n\t\t\t\t20180712075154_BIB70","doi-asserted-by":"crossref","unstructured":"Mulholland EK (2000) Conjugate pneumococcal vaccines: an overview. Med J Aust, 173 (Suppl), S48\u201350.","DOI":"10.5694\/j.1326-5377.2000.tb139415.x"},{"key":"key\n\t\t\t\t20180712075154_BIB71","doi-asserted-by":"crossref","unstructured":"Lipsitch M , Dykes JK, Johnson SE et al. (2000) Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model. Vaccine, 18, 2895\u2013901.","DOI":"10.1016\/S0264-410X(00)00046-3"},{"key":"key\n\t\t\t\t20180712075154_BIB72","doi-asserted-by":"crossref","unstructured":"Hoskins J , Alborn WE Jr, Arnold J et al. (2001) Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol, 183, 5709\u201317.","DOI":"10.1128\/JB.183.19.5709-5717.2001"},{"key":"key\n\t\t\t\t20180712075154_BIB73","doi-asserted-by":"crossref","unstructured":"Tettelin H , Nelson KE, Paulsen IT et al. (2001) Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science, 293, 498\u2013506.","DOI":"10.1126\/science.1061217"},{"key":"key\n\t\t\t\t20180712075154_BIB74","doi-asserted-by":"crossref","unstructured":"Dopazo J , Mendoza A, Herrero J et al. (2001) Annotated draft genomic sequence from a Streptococcus pneumoniae type 19F clinical isolate. Microb Drug Resist, 7, 99\u2013125.","DOI":"10.1089\/10766290152044995"},{"key":"key\n\t\t\t\t20180712075154_BIB75","doi-asserted-by":"crossref","unstructured":"Jedrzejas MJ , Lamani E, Becker RS (2001) Characterization of selected strains of pneumococcal surface protein A. J Biol Chem, 276, 33121\u20138.","DOI":"10.1074\/jbc.M103304200"},{"key":"key\n\t\t\t\t20180712075154_BIB76","doi-asserted-by":"crossref","unstructured":"Jedrzejas MJ (2001) Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev, 65, 187\u2013207.","DOI":"10.1128\/MMBR.65.2.187-207.2001"},{"key":"key\n\t\t\t\t20180712075154_BIB77","doi-asserted-by":"crossref","unstructured":"Hakenbeck R , Balmelle N, Weber B, Gardes C, Keck W, de Saizieu A (2001) Mosaic genes and mosaic chromosomes: intra- and interspecies genomic variation of Streptococcus pneumoniae. Infect Immun, 69, 2477\u201386.","DOI":"10.1128\/IAI.69.4.2477-2486.2001"},{"key":"key\n\t\t\t\t20180712075154_BIB78","doi-asserted-by":"crossref","unstructured":"Rosenow C , Ryan P, Weiser JN et al. (1997) Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol, 25, 819\u201329.","DOI":"10.1111\/j.1365-2958.1997.mmi494.x"},{"key":"key\n\t\t\t\t20180712075154_BIB79","doi-asserted-by":"crossref","unstructured":"Gosink KK , Mann ER, Guglielmo C, Tuomanen EI, Masure HR (2000) Role of novel choline binding proteins in virulence of Streptococcus pneumoniae. Infect Immun, 68, 5690\u20135.","DOI":"10.1128\/IAI.68.10.5690-5695.2000"},{"key":"key\n\t\t\t\t20180712075154_BIB80","doi-asserted-by":"crossref","unstructured":"Wu HY , Nahm MH, Guo Y, Russell MW, Briles DE (1997) Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis, 175, 839\u201346.","DOI":"10.1086\/513980"},{"key":"key\n\t\t\t\t20180712075154_BIB81","doi-asserted-by":"crossref","unstructured":"Berry AM , Paton JC (2000) Additive attenuation of virulence of Streptococcus pneumoniae by mutation of the genes encoding pneumolysin and other putative pneumococcal virulence proteins. Infect Immun, 68, 133\u201340.","DOI":"10.1128\/IAI.68.1.133-140.2000"},{"key":"key\n\t\t\t\t20180712075154_BIB82","doi-asserted-by":"crossref","unstructured":"Areas AP , Oliveira ML, Miyaji EN et al. (2004) Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. Biochem Biophys Res Commun, 321, 192\u20136.","DOI":"10.1016\/j.bbrc.2004.06.118"},{"key":"key\n\t\t\t\t20180712075154_BIB83","doi-asserted-by":"crossref","unstructured":"Wizemann TM , Heinrichs JH, Adamou JE et al. (2001) Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun, 69, 1593\u20138.","DOI":"10.1128\/IAI.69.3.1593-1598.2001"},{"key":"key\n\t\t\t\t20180712075154_BIB84","doi-asserted-by":"crossref","unstructured":"Adamou JE , Heinrichs JH, Erwin AL et al. (2001) Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun, 69, 949\u201358.","DOI":"10.1128\/IAI.69.2.949-958.2001"},{"key":"key\n\t\t\t\t20180712075154_BIB85","doi-asserted-by":"crossref","unstructured":"Lau GW, Haataja S, Lonetto M et al. (2001) A functional genomic analysis of type 3 Streptococcus pneumoniae virulence. Mol Microbiol 2001;40, 555\u201371","DOI":"10.1046\/j.1365-2958.2001.02335.x"},{"key":"key\n\t\t\t\t20180712075154_BIB86","doi-asserted-by":"crossref","unstructured":"Polissi A , Pontiggia A, Feger G et al. (1998) Large-scale identification of virulence genes from Streptococcus pneumoniae. Infect Immun, 66, 5620\u20139.","DOI":"10.1128\/IAI.66.12.5620-5629.1998"},{"key":"key\n\t\t\t\t20180712075154_BIB87","doi-asserted-by":"crossref","unstructured":"Kasper DL , Paoletti LC, Wessels MR et al. (1996) Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest, 98, 2308\u201314.","DOI":"10.1172\/JCI119042"},{"key":"key\n\t\t\t\t20180712075154_BIB88","doi-asserted-by":"crossref","unstructured":"Baker CJ , Paoletti LC, Rench MA et al. (2000)Use of capsular polysaccharide\u2013tetanus toxoid conjugate vaccine for type II group B streptococcus in healthy women. J Infect Dis, 182, 1129\u201338.","DOI":"10.1086\/315839"},{"key":"key\n\t\t\t\t20180712075154_BIB89","doi-asserted-by":"crossref","unstructured":"Paoletti LC , Kasper DL (2002) Conjugate vaccines against group B streptococcus types IV and VII. J Infect Dis, 186, 123\u20136.","DOI":"10.1086\/341073"},{"key":"key\n\t\t\t\t20180712075154_BIB90","doi-asserted-by":"crossref","unstructured":"Brewer TF (2000) Preventing tuberculosis with bacillus Calmette\u2013Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis, 31 (Suppl 3), S64\u20137.","DOI":"10.1086\/314072"},{"key":"key\n\t\t\t\t20180712075154_BIB91","doi-asserted-by":"crossref","unstructured":"Colditz GA , Brewer TF, Berkey CS et al. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA, 271, 698\u2013702.","DOI":"10.1001\/jama.1994.03510330076038"},{"key":"key\n\t\t\t\t20180712075154_BIB92","doi-asserted-by":"crossref","unstructured":"Fine PE (1989) The BCG story: lessons from the past and implications for the future. Rev Infect Dis, 11 (Suppl 2), S353\u20139.","DOI":"10.1093\/clinids\/11.Supplement_2.S353"},{"key":"key\n\t\t\t\t20180712075154_BIB93","doi-asserted-by":"crossref","unstructured":"Nor NM , Musa M (2004) Approaches towards the development of a vaccine against tuberculosis: recombinant BCG and DNA vaccine. Tuberculosis (Edinb), 84, 102\u20139.","DOI":"10.1016\/j.tube.2003.08.011"},{"key":"key\n\t\t\t\t20180712075154_BIB94","doi-asserted-by":"crossref","unstructured":"Horwitz MA , Harth G, Dillon BJ, Maslesa-Galic S (2000) Recombinant bacillus Calmette\u2013Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad. Sci USA, 97, 13853\u20138.","DOI":"10.1073\/pnas.250480397"},{"key":"key\n\t\t\t\t20180712075154_BIB95","doi-asserted-by":"crossref","unstructured":"Pym AS , Brodin P, Majlessi L et al. (2003) Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med, 9, 533\u20139.","DOI":"10.1038\/nm859"},{"key":"key\n\t\t\t\t20180712075154_BIB96","doi-asserted-by":"crossref","unstructured":"Smith DA , Parish T, Stoker NG, Bancroft GJ. (2001) Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun, 69, 1142\u201350.","DOI":"10.1128\/IAI.69.2.1442-1150.2001"},{"key":"key\n\t\t\t\t20180712075154_BIB97","doi-asserted-by":"crossref","unstructured":"Delogu G , Li A, Repique C, Collins F, Morris SL (2002) DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis. Infect Immun., 70, 292\u2013302.","DOI":"10.1128\/IAI.70.1.292-302.2002"},{"key":"key\n\t\t\t\t20180712075154_BIB98","doi-asserted-by":"crossref","unstructured":"Palendira U , Kamath AT, Feng CG et al. (2002) Coexpression of interleukin-12 chains by a self-splicing vector increases the protective cellular immune response of DNA and Mycobacterium bovis BCG vaccines against Mycobacterium tuberculosis. Infect Immun, 70, 1949\u201356.","DOI":"10.1128\/IAI.70.4.1949-1956.2002"},{"key":"key\n\t\t\t\t20180712075154_BIB99","doi-asserted-by":"crossref","unstructured":"McShane H , Brookes R, Gilbert SC, Hill AV (2001) Enhanced immunogenicity of CD4(+) T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun, 69, 681\u20136.","DOI":"10.1128\/IAI.69.2.681-686.2001"},{"key":"key\n\t\t\t\t20180712075154_BIB100","doi-asserted-by":"crossref","unstructured":"West D , Reddin K, Matheson M et al. (2001) Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect Immun, 69, 1561\u20137.","DOI":"10.1128\/IAI.69.3.1561-1567.2001"},{"key":"key\n\t\t\t\t20180712075154_BIB101","doi-asserted-by":"crossref","unstructured":"Danve B , Lissolo L, Mignon M et al. (1993) Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine, 11, 1214\u201320.","DOI":"10.1016\/0264-410X(93)90045-Y"}],"container-title":["British Medical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bmb\/article-pdf\/72\/1\/65\/25152190\/ldh041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T21:39:08Z","timestamp":1586209148000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bmb\/article\/72\/1\/65\/272848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,3,31]]},"published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bmb\/ldh041","relation":{},"ISSN":["1471-8391","0007-1420"],"issn-type":[{"value":"1471-8391","type":"electronic"},{"value":"0007-1420","type":"print"}],"subject":[],"published-other":{"date-parts":[[2004]]},"published":{"date-parts":[[2004,1,1]]}}}